Physician profile
Ayushi Dixit
NPI 1285097626
$14,492.00
in general payments reported to CMS, 2019-2025
34 companies · $12K in 2025
The $12K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $380 · 2021: $110 · 2022: $439 · 2023: $468 · 2024: $1,107 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $2,416 · Education: $16.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,016.00 |
| Food and Beverage | $2,415.52 |
| Education | $16.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $11,879.69 | 2023-2025 | |
| Amgen INC. | $591.44 | 2020-2025 | Evenity, Repatha, Tepezza |
| Lilly USA, LLC | $281.01 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $197.97 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $130.76 | 2022-2025 | Korlym |
| Esperion Therapeutics, INC. | $124.69 | 2020 | |
| Xeris Pharmaceuticals, INC. | $122.85 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $117.39 | 2023-2025 | Omnipod |
| Abbott Laboratories | $114.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.64 | 2021-2023 | Cuvitru, Entyvio |
| Merck Sharp & Dohme LLC | $91.54 | 2022-2025 | Verquvo, Steglatro, Lagevrio |
| Janssen Biotech, INC. | $88.45 | 2022 | |
| Medtronic, INC. | $83.44 | 2023-2024 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.53 | 2021-2024 | Jardiance |
| Asensus Surgical, INC. | $63.84 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $53.52 | 2025 | Gamma |
| Recordati_rare_diseases_inc. | $45.61 | 2024-2025 | Isturisa, Signifor Lar |
| Pfizer INC. | $30.00 | 2022 | |
| Glaxosmithkline, LLC. | $29.31 | 2022-2023 | Shingrix, Bexsero |
| Ultragenyx Pharmaceutical INC. | $28.80 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $27.80 | 2024-2025 | |
| Incyte Corporation | $23.05 | 2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $20.83 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $19.77 | 2024 | |
| Inspire Medical Systems, INC. | $19.32 | 2024 | Inspire |
| Mannkind Corporation | $17.87 | 2024 | |
| Agios Pharmaceuticals, INC. | $16.71 | 2023 | Pyrukynd |
| Celltrion USA INC. | $16.60 | 2024 | Zymfentra |
| Genzyme Corporation | $15.48 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.00 | 2022 | |
| Fresenius Kabi USA, LLC | $14.59 | 2023 | |
| Cequr Corporation | $13.91 | 2023 | Cequr Simplicity |
| Currax Pharmaceuticals LLC | $13.77 | 2023 | Contrave |
| Amneal Pharmaceuticals LLC | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayushi Dixit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.